PubMed Health⌕ Search

Biomedical subjects

H Bisler

Publications and source records attributed to H Bisler.

14 recordsLinked to original sources
PubMed1997

Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebo-controlled double-blind trial.

For the first time efficacy and safety of a new prostaglandin E1 (PGE1) regimen in the treatment of intermittent claudication were evaluated in a randomized, double-blind, placebo-controlled multicenter clinical trial. The study involved 213 outpatients with a maximum walking distance of 50 to 200 m measured on the treadmill (3 km/hr, 12% grade). After a 2-week run-in phase they received a 2-hour intravenous infusion of 60 micrograms PGE1 or placebo 5 days a week for 4 weeks. It was followed by a 4-week interval treatment with the same medication administered only twice a week. Patients were monitored for 3 months when they received no study medication. In the PGE1 group the intention-to-treat analysis (n = 208) revealed an increase in walking distance after 4 weeks of 75% (placebo, 43%). At the end of the interval treatment the walking distance had improved to 101% (placebo, 60%). The results remained virtually constant during follow-up (PGE1, 104%, placebo, 63%). Between-group comparisons showed significant differences in favor of PGE1 for all three time points of measurement (p < 0.05, p < 0.01, and p < 0.05). PGE1 was well tolerated; the rate of adverse reactions related to the treatment was 12.8% (placebo, 7.7%). In summary, these results show that the new PGE1 regimen is effective and safe in the treatment of outpatients with intermittent claudication.

Aged↗
PubMed1993

[Transcutaneous absorption of non-steroidal antirheumatics. Clinical study under a new model for investigation of pharmacokinetics].

The feasibility of the bilateral vein stripping model for the investigation of the transcutaneous absorption of a non-steroidal antirheumatic drug (NSAID) was examined. After application of a 1% solution of indomethacin (Elmetacin, CAS 53-86-1) at one leg (steady state) plasma and vein tissue of both sides was taken at the same time. The mean indomethacin plasma levels of 19 female patients were 7 ng/ml, in the vein tissue of the application side 280 ng/g and at the opposite side 80 ng/g. The tissue levels in the veins are in the same range as in the target tissues of transcutaneous antirheumatic therapy. Therefore the model is considered useful for the investigations of the pharmacokinetics of topically applied NSAID.

Administration, Topical↗
PubMed1991

[The Essen walking training model].

Patients suffering from intermittant claudiation should be treated mainly by walking. Following the example of Weidinger and Bachl, who established in Vienna 1981 for these patients walking groups, we also started with this treatment in Essen. Since 1988 117 patients, 68 men and 49 women took part regularly at least 3 months in one of the walking groups. Only 9% of the patients could not improve their walking distance.

Aged↗
PubMed1991

[Walking training as basic therapy of stage II peripheral arterial occlusive disease--success despite advanced age and concomitant diseases].

64 patients (60 to 83 years old) with intermittent claudication underwent a six months lasting supervised exercise walk training. Most of them suffered from concomitant disease impairing walking performance or just weakness by age. Walking distance was measured in the beginning and after 3 and 6 months. We found an improvement in walking distance in all groups (60-64 years: 273%; 75-83 years: 196.6%) So we recommend to apply walk training to a much more patients even with concomitant disease are of old age.

Aged↗
PubMed1991

[Case report: acute infrarenal aortic occlusion and leg vein thrombosis in heparin-induced thrombocytopenia].

Heparinassociated thrombocytopenia has been reported for over 35 years. This reaction can result in serious thromboembolic complications. The primary mechanism responsible for this reaction is thought to be an immunologic process. The author reports a severe thrombocytopenia, acute thrombotic occlusion of the leg, acute aortal thrombosis, deep-vein thrombosis and pulmonary emboli occurred simultaneously in a 75-year-old woman within 11 days of starting a subcutaneous low-dose heparin prophylaxis.

Aged↗
PubMed1986

[Effects of horse-chestnut seed extract on transcapillary filtration in chronic venous insufficiency].

The effect of horse-chestnut seed extract (standardized on aescin; Venostasin retard) was assessed in a randomized placebo-controlled crossover double-blind trial of 22 patients with proven chronic venous insufficiency by measuring the capillary filtration coefficient and the intravascular volume of the lower leg by venous-occlusion plethysmography. Three hours after taking two capsules of Venostasin (600 mg; each capsule containing 50 mg aescin) the capillary filtration coefficient had decreased by 22%, whereas after administration of an identical-looking placebo capsule it rose but slightly over three hours. The difference in the effect of Venostasin and placebo is statistically significant (P = 0.006). The intravascular volume was reduced 5% more after Venostasin than the placebo, but this is not statistically significant. It is concluded that Venostasin has an inhibitory effect on oedema formation via a decrease in transcapillary filtration and thus improves oedema-related symptoms in venous diseases of the legs.

Capillary Permeability↗
PubMed1984

Buflomedil in arterial occlusive disease: results of a controlled multicenter study.

In a double-blind, randomised multicentre study buflomedil, a vasoactive substance, was compared with placebo in the treatment of 93 patients with chronic arterial occlusive disease. After a run-in period of four weeks the patients received either buflomedil (600 mg daily) or placebo over 12 weeks. The pain-free and the total walking distances improved significantly in both groups. However, the differences in the improvement between the two groups were highly significant and in favour of buflomedil: for the pain-free walking distance p less than 0.001 and for the total walking distance p less than 0.01. The results indicate that buflomedil has a beneficial effect on the symptoms and lengthens the walking distance in patients with arterial occlusive disease.

Aged↗
PubMed1980

[Injuries of blood vessels due to gynaecologic laparoscopy (author's transl)].

During gynaecological laparoscopy, in rare cases, life threatening injuries occur. The report describes three cases of vascular injuries performed due to vascular surgery. To avoid such vascular lesions serves near by to observe and take precautions in the hard altered topographic connexions between peritoneal cover and abdominal vessels during the typical gynaecological case. Every laparoscopist should know the symptoms of the complications beforehand, and he should be able also to perform the vascular sutures.

Adult↗
PubMed1978

[Early and late results in the prevention of pulmonary embolism and caval patency after implantation of caval clips according to Adams--De Weese as compared to Mobin-Uddin umbrella filters (author's transl)].

A collective of 56 female and 54 male patients between 15 and 78 years were operated to prevent pulmonary embolism. 27 umbrella filters and 83 vena cava clips were implanted. Postoperative mortality was 15 per cent after umbrella filter implantation as compared to 0 per cent after clip application. 35 clip and 9 filter implantations were followed up by cavographic examination. Venograms were classified in three types according to caval patency. A significantly higher number of complications were observed after filter implantation. On the basis of a flow physics hypothesis an explanation is suggested for the liability to caval thrombosis after filter implantation. An evaluation of both operative methods and their indications is given.

Filtration↗
PubMed1977

[Broncho-cutaneous fistula by myocardial pacemaker-elektrode infection (author's transl)].

A rare complication of pacemaker therapy is reported. Shortening and retaining of myocardial electrodes after pocket infection of the pacemaker resulted in the incidence of broncho-cutaneous fistula. One similar case has been presented in the literature. Both the conservative and the operative therapy are discussed. In this report our procedure with pacemaker infections is presented.

Aged↗
PubMedDate not supplied

Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost.

Severe pain at rest is a major symptom of advanced peripheral arterial occlusive disease (PAOD). Preliminary studies of treatment with iloprost, a prostacyclin analogue, showed encouraging results in patients with ischaemic rest pain. Therefore a randomized, placebo-controlled multicentre study was undertaken in 113 patients admitted to hospital with rest pain of at least 2 weeks duration caused by severe PAOD. The patients were randomly assigned to receive 2-week placebo or iloprost infusions for 6 hours per day at a dose of 0.5-0.2 ng/kg/min in addition to conventional care. Demographic data and arteriographic findings were similar in the two groups. Eleven patients withdrew from the study before completion and 102 patients could be included in the final analysis. Significantly more patients in the iloprost group (62.5% of 48) than in the placebo group (42.6% of 54) had complete relief of pain without analgesic therapy during at least five consecutive days at the end of the treatment period (p less than 0.05, chi 2-test). Facial flush, headache and nausea were the most common side effects during iloprost infusion. Serious adverse reactions did not occur. Thus, a 2-week iloprost infusion was shown to be safe and effective as a treatment for ischaemic rest pain caused by PAOD.

Adult↗